Hansen, Mueller Industries director, sells $105,710 in stock
DUBLIN - Goldman Sachs & Co. LLC disclosed its trading activity in Avadel Pharmaceuticals PLC shares, reporting a 2.02% long position and 1.02% short position following dealings on October 23, 2025.
According to a regulatory filing submitted Thursday under Irish Takeover Panel rules, Goldman Sachs held 1,973,235 shares in long positions and 996,129 shares in short positions in Avadel after the transactions.
The disclosure, required for exempt principal traders without recognized intermediary status, detailed numerous purchases and sales of Avadel’s ordinary shares. The transactions occurred at prices ranging from $18.49 to $18.57 per share.
The filing showed Goldman Sachs purchased 29,900 shares through standard market transactions while executing multiple sales totaling over 30,000 shares. Additionally, the firm conducted various securities lending transactions, including loan returns and new borrowings.
Goldman Sachs also reported derivatives transactions involving contracts for difference (CFDs), including opening a short position of 34,464 securities and reducing existing positions.
The firm identified itself as an advisor to Avadel Pharmaceuticals in the disclosure, which was made in compliance with Rule 38.5(b) of the Irish Takeover Panel Act.
The regulatory filing is standard practice for financial institutions involved in takeover situations under Irish securities regulations, providing transparency regarding trading activities of parties connected to potential acquisition targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.